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Transfusion independence and survival in patients with acute 
myeloid leukemia treated with 5-azacytidine 
 
Reanalysis of the CALGB (1) and AZA001 (2) studies in advanced myelodysplastic 
syndrome (MDS) suggests that 5-azacytidine (AZA) is effective for acute myeloblastic 
leukemia (AML) with <30% bone marrow blasts. Most AML patients are elderly (>65 
years old) and unfit for intensive chemotherapy and allogeneic transplantation (3); 
prognosis is dreadful with median survival of a few months (4). For these patients 
appropriate treatments are best supportive care or low dose cytarabine (3). 
Compared with best supportive care, low-dose cytarabine more frequently induces 
complete remissions (18% vs 1%) and prolongs survival (3.8 vs 2.5 months) (3). AZA 
targets DNA methyltransferase and reactivates quiescent genes (5), decreases 
leukemic cell proliferation and induces cell differentiation. In higher risk MDS or in 
AML with <30% bone marrow blasts (6), AZA outperformed conventional care (best 
supportive care, low-dose cytarabine, and intensive chemotherapy) (7) with longer 
hematologic improvement and transfusion independence (TI) (5). Here, we 
postulated that patients unfit for standard AML chemotherapy might also benefit from 
AZA, irrespectively of bone marrow blast count. 
We systematically reviewed charts of all patients treated with AZA at our institution 
between January 1st 2007 and December 31st 2011, and identified 52 consecutive 
AML patients. These patients were not eligible for intensive chemotherapy due to 
advanced age (n=33) or comorbidities (n=9), or were refractory to initial intensive 
chemotherapy (n=10). AZA was administered at 100mg/m2 sc day 1-5, over 28-day 
cycles. This schedule is equivalent to standard day 1-7 MDS treatment (8) and allows 
weekday outpatient treatment (2). Therapy was continued until disease progression, 
as survival benefit is extended beyond achievement of best response (9). Indication 
for transfusion was based on symptoms, comorbidities, and laboratory values 
(generally Hb<80g/l and PLT<10G/l). Transfusion independence was defined as ≥8 
weeks without red blood cell (RBC-TI) and/or platelet (PLT-TI) transfusion (1, 7). The 
indication to treat patients with baseline RBC-TI was based on appearance of 
agranulocytosis (n=3), high peripheral blood or marrow blast counts (n=5), and/or 




of AZA to death. Five surviving patients were censored on December 31th 2011. The 
median follow-up of censored patients was 12.2 months. Statistical analysis was 
performed using Stata software (Statacorp LP, College Station, Texas, USA). 
At baseline, 15% (n=9) of our patients had RBC-TI and 25% (n=13) PLT-TI. Median 
overall survival of the 52 enrolled patients was 8.6 months and 12-month survival 
rate was 28% [95CI 15-43%]. We excluded 14 patients from transfusion and survival 
analyses, since they did not reach the minimal 8-week observation period. Among 
them, 11 patients received only 1 cycle of AZA and 3 received 2 cycles. Treatment 
was interrupted due to premature death or disease progression (n=12), or availability 
of a donor for allogeneic stem cell transplantation (n=2). Among these 14 patients, 3 
had RBC-TI and 3 had PLT-TI at the onset of therapy. Median OS was 1.3 months 
[0.5-23.7].  
Characteristics of the 38 remaining patients are presented in Table 1. Patients with 
baseline or acquired RBC-TI (n=22) were grouped and compared to patients that 
never reached RBC-TI (n=16). Among patients with transfusion independence, 6 had 
RBC-TI at baseline while 16 achieved RBC-TI under therapy. Except for age, which 
was older for patients with RBC-TI, we found no differences in baseline 
characteristics. Our 38 patients received a median of 6 [3-20] cycles of AZA. Overall 
response rate was 23% (n=9), distributed in 7 complete response with incomplete 
blood count recovery (CRi) and 2 partial remission (PR) (10). The residual 29 
patients exhibited resistant disease (RD, 76%). RD status was equally distributed 
among transfusion independent and transfusion dependent groups (13 vs 16). 
RBC-TI at baseline or under AZA therapy (n=22) was associated to prolonged 
survival. The median OS of transfusion independent patients was 11.1 months vs. 
5.0 months for transfusion dependent patients (12-month OS 40% [95CI 19-60%] vs. 
13% [95CI 2-32%], P=0.0006, Figure 1A). Presence of transfusion independence at 
baseline (n=6) or its achievement under treatment (n=16) had similar survival 
outcome (median OS 10.7 vs. 11.9, 12-month OS 40% [95CI 17-63%] vs. 45% [95CI 
5-75%], P=NS, Figure 1B). Median OS of transfusion dependent patients reported 
here (5.0 months) is similar to that observed for patients enrolled in AML14 trial who 
received best supportive care (2.5 months) or low-dose cytarabine (3.8 months) (3). 




5.4 months, 12-month OS 32% [95CI 14-52%] vs. 21% [95CI 5-45%], P=0.053). The 
median delay to reach RBC-TI or PLT-TI after therapy initiation was 85 days [60-143] 
and 73 days [35-154], respectively (~3 AZA cycles). As observed in MDS patients 
(1),transfusion independence was achieved in all responding patients by the end of 
the 6th cycle . In patients with baseline RBC-TI, the median duration of transfusion 
independence was 22 weeks [8 to 42]. When obtained in response to AZA, the 
median duration of transfusion independence reached 30 weeks [10 to 88]. In our 
country, blood product expenses in transfusion dependent patients (median 5 RBC 
and 6 PLT transfusions per month for our collective) were comparable to those of 
continued AZA therapy in transfusion independent patients.  
Univariate analysis of survival showed significant differences for peripheral blood 
blast count ≥20%, relapsed/refractory disease, baseline PLT-TI and, baseline or 
acquired RBC-TI. Interestingly, BM blast level was not predictive of survival or 
response to treatment. In multivariate analysis, baseline or acquired RBC-TI 
remained the single parameter favorably affecting survival (HR 0.36 [95CI 0.16-0.77], 
P=0.009).  
In conclusion, we report here for the first time that AZA can induce transfusion 
independence in half of previously transfusion dependent patients and that 
transfusion independence is a strong prognostic factor in unfit AML patients. 
Observations made in MDS (11) may now be extended to AML. In addition, AZA may 
improve quality of life by reducing requirements for transfusions and anemia 
symptoms. Prospective randomized trials are required to validate these observations 
in larger cohorts.  
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Table 1. Baseline characteristics of study groups according to RBC transfusion 
independence. 






N  38 22 16  
Age Years 68 [25-86] 72 [62-83] 66 [39-80] 0.04 
 ≥70 21 (55%) 14 (67%) 7 (41%) NS 
Gender Female 24 (63%) 14 (67%) 10 (59%) NS 
Lab values at baseline     
Hb g/l 85 [72-125] 87 [73-125] 82 [72-108] NS 
PLT G/l 38 [7-517] 40 [7-128] 37 [14-517] NS 
WBC G/l 3.1 [0.6-36.6] 3.9 [1.4-21.4] 2.9 [0.6-36.6] NS 
ANC G/l 0.5 [0.0-6.0] 0.6 [0.0-3.1] 0.3 [0.1-6.0] NS 
PB blasts % 14 [0-91] 10 [0-91] 39 [0-90] NS 
BM blasts % 70 [20-90] 73 [20-90] 70 [20-90] NS 
 ≥30% 29 (83%) 15 (80%) 14 (87%) NS 
 ≥50% 21 (60%) 11 (55%) 10 (67%) NS 
RBC units over 8 weeks  
prior to AZA start 
2 [0-16] 1 [0-16] 2 [0-16] NS 
Cytogenetic Favorable 3 (8%) 2 (10%) 1 (6%)  
risk group* Intermediate 21 (64%) 12 (57%) 11 (65%) NS 
 Adverse 11 (29%) 7 (33%) 4 (24%)  
Diagnosis Primary AML 16 (42%) 8 (28%) 8 (62%)  
 Transformed MDS 17 (45%) 14 (63%) 3 (19%) NS 




Months 0.4 [0.0-12.9] 0.3 [0.1-12.6] 0.6 [0.0-13.0] NS 
For continuous data median is shown, [ ] range. RBC-TI, red blood cell transfusion independence. 
*Definition of cytogenetic groups was according to HOVON classification (12), NA for 1 patient in 





Figure 1. Survival according to RBC-transfusion independency.  
A. Overall survival of patients according to transfusion needs. We analyzed 38 patients : 22 
RBC-transfusion independent (blue) and 16 RBC-transfusion dependent (red). OS 11.1 vs 
5.0 months, P=0.0006. Twelve-month survival rate were 40% [95CI 19-60%] and 13% [95CI 
2-32%] respectively. B. Overall survival of patients with transfusion independence (TI) 
according to baseline transfusion needs (n=22). Median OS was 10.7 months for baseline TI 
(n=6, blue) vs. 11.9 months for TI acquired under AZA (n=16, red), 12-month OS 40 [95CI 
17-63%] vs. 45% [95CI 5-75%], P=NS. 
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